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Nonalcoholic Fatty Liver Disease in 
10-16-Year-Old Children
INTRODUCTION
NAFLD is characterised by hepatic fat accumulation despite low 
amounts of alcohol intake, presenting with hepatomegaly signs [1]. 
NAFLD is a metabolic disorder frequently diagnosed in western and 
eastern countries, resulting in increased liver and cardiovascular 
disease-related morbidity and mortality [2]. The prevalence of NAFLD 
is 34% in adults [3]. Most NAFLD patients are 40-60 years-old but 
children aged over 10 years are also likely to develop NAFLD [4].
NAFLD is now considered an independent condition as with obesity, 
hypertension and diabetes. It is widely acknowledged that NAFLD 
has close association with central obesity. However, 20-40% of 
NAFLD patients are not obese. It has been widely accepted that 
hyperlipidaemia leads to NAFLD [1].
The cause and treatment for NAFLD have not yet been definitely 
determined [1]. Early diagnosis of this disease is essential and 
its treatment can prevent progression to cirrhosis [5,6]. Lifestyle 
interventions such as exercise and weight loss are the only widely 
accepted treatments for this disease but they are difficult to adhere 
to for most NAFLD patients [5].
Camellia sinensis (Green tea) is a medicinal plant that originated 
from China and South East Asia thousands of years ago and is one 
of the most widely known beverages across the world [7].
In green tea drinkers, a significant reduction has been reported 
in the risk of developing hepatic diseases such as hepatocellular 
carcinoma, liver cirrhosis, liver steatosis, chronic liver disease and 
hepatitis [8]. C. sinensis is one of the richest sources of flavonoids 
with different health benefits [9].
Green Tea Polyphenol (GrTPs) have different health benefits [9]. GrTPs 
have antimutagenic, antioxidant, antidiabetic, antibacterial and anti-
inflammatory properties [10]. GrTPs prevents hyperlipidaemia in the 
liver and causes increase in energy consumption, oxidation of fat 
and decrease in the body fat percentage [11]. In animals on high-
fat diets that received C. sinensis and GrTPs, lower Triglyceride 
(TG) and cholesterol levels and higher faecal fat levels compared 
to controls were observed [12]. C. sinensis therefore has potential 
to control the weight of obese people. In vitro, C. sinensis extract 
is involved in the process of lipid emulsification, inhibition of fatty 
acids activity and synthesis as well as decrease in the hepatic fat 
accumulation [5,13].
The main polyphenolic compounds of C. sinensis are catechins, 
such as Epigallocatechingallate (EGCG), epigallocatechin, 
epicatechingallate, and epicatechin, which have been reported to 
have beneficial effects on human health [13]. Increased serum levels 
of liver enzymes indicate liver injury and ALT is the most important 
marker of liver injury [14]. The increased liver enzyme levels can be 
observed alongside simple steatosis in over 50% of the patients, 
and are observed in approximately 80% of patients with advanced 
NAFLD [15].
To treat NAFLD patients, it is necessary to use plant-based drugs 
that cause comparatively fewer side-effects and are available and 
inexpensive as well as effective in improving liver enzymes, hepatic 
lipids, and liver morphology with regard to unsatisfactory effects of 
weight loss and exercise protocols as well as inefficiency, long-term 
effects and serious side-effects of certain chemical drugs [5,16,17]. 
Recent studies have highlighted the necessity of conducting further 
studies for confirming the effects of flavonoids, C. sinensis and its 
extract on liver injury [1,18].
Although a number of studies have been conducted in different 
countries, most of them have been conducted on mice [5,12,19,20], 
and few clinical trials have investigated this issue [21]. This study 
aimed to investigate the effect of C. sinensis on NAFLD, fatty liver 
NouShiN RoStampouR1, KaRam ali KaSiRi2, elham haShemi-dehKoRdi3, aBdol majid taheRi4, 
aNahita faRahzad BRoujeNi5, mahmoud RafieiaN-Kopaei6 
 
Keywords: Alanine aminotransferase, Aspartate aminotransferase, Green tea extract, Nonalcoholic steatohepatitis
ABSTRACT
Introduction: Nonalcoholic Fatty Liver Disease (NAFLD) is 
characterised by fat accumulation in the liver. Treatment of 
NAFLD in children is an important issue but the options are 
limited. Green tea has antioxidant and anti-hyperlipidemic 
effects but studies; on the effect of green tea in children are 
limited.
Aim: To investigate effect of green tea on NAFLD in children.
Materials and Methods: In this study, 52 children aged 10-16 
years with NAFLD were divided into two groups of 26 each: 
Intervention and control. For both groups, modification of diet 
and intensification of physical activity were prescribed for 
three months. Intervention group was also treated with green 
tea tablets. Sonography and measurements of liver enzymes 
{Alanine Aminotransferase (ALT) and Aspartate Aminotransferase 
(AST)}, lipid profile and Body Mass Index (BMI) were conducted 
before and after the intervention. The data were analysed by the 
Statistical Package for the Social Sciences (SPSS) version 19.0 
using ANCOVA.
Results: After treatment with green tea, fatty liver grade decreased 
significantly in the intervention group compared to control group 
(p<0.0001). In addition, this treatment caused significant decrease 
in ALT, AST, and triglyceride levels and significant increase in 
High-Density Lipoprotein (HDL) level (p<0.05), but Low-Density 
Lipoprotein (LDL) level did not decrease significantly in the 
intervention group compared to control.
Conclusion: Oral prescription of green tea was effective in 
improving fatty liver grade, decreasing hepatic fat accumulation 
and improving liver function, weight loss and reducing ALT and 
AST without any side effects. These effects can be due to green 
tea compounds such as polyphenols especially catechin and 
antioxidant and anti-hyperlipidemic effects.
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RESULTS
A total of 52 patients with NAFLD participated in this study. Thirteen 
girls and thirteen boys were participated in each of the two groups. 
The age range of the participants was 10-16 years with mean age 
of 12.53±1.99 years and 11.84±1.53 years in intervention group 
and control group, respectively. There was no significant difference 
in age between the two groups (p=0.16). The mean weight of 
intervention group was 63.76±16.25 kg and that of control group 
was 57.38±12.74 kg; and the mean height of intervention group was 
148.84±8.15 cm and that of control group was 150.255±49.11 cm. 
There was no significant difference in weight and height between 
the two groups (p=0.9 and 0.62, respectively).
In the control group, before intervention, 22 children had Grade 1 
fatty liver and four children had Grade 2 fatty liver. After intervention, 
21 children had Grade 1 fatty liver and five children had Grade 2 
fatty liver. In the intervention group, before intervention, 19 children 
had Grade 1 fatty liver and seven children had Grade 2 fatty liver. 
After intervention, 10 children had grade 1 fatty liver and no child 
had Grade 2 fatty liver. In 16 children, fatty liver did not change and 
their ultrasound results were normal. Changes in fatty liver grade 
were significant in intervention group and non-significant in control 
group [Table/Fig-1].
grade, TG and cholesterol levels, the body weight and liver enzymes 
in children aged 10-16 years.
MATERIALS AND METHODS
This Quasi-experimental study (single-blind clinical trial) was done in 
a university endocrine clinic in Shahrekord, southwest of Iran from 
November 2014 to October 2015. The study was approved by the 
Ethics Committee of Shahrekord University of Medical Sciences 
(code: IR.SKUMS.REC.1394.57). The present study population 
consist of 10-16 years old children. The sample size of this study 
was estimated 26 people in each group according to a formula 
of sample size calculation (Equation 1) and taking its parameters 
into account:
Equation 1:
Children with body mass index (BMI) ≥85th percentile or 
hypertriglyceridaemia (TG >150 mg/dL and/or cholesterol >200 mg/
dL) [22] and apparently healthy were examined by a paediatric 
endocrinologist and gastroenterologist. A detailed history and 
physical examination was done for all patients. Diagnosis was 
confirmed by ultrasound and laboratory evidence of fatty liver. 
The authors selected children with fatty liver on sonography and 
increased AST and ALT levels after exclusion of other causes. 
Grading of the fatty liver was conducted according to the protocol 
described by Saverymuttu SH et al., [23]. All the imaging was done 
by the same radiologist who was unaware of intervention.
The participants were selected by convenience sampling and were 
divided into two groups after they provided informed consent to 
participate in the study and were ensured that the data would be kept 
private. The present authors used minimisation for randomisation. 
The data on demographics (age, sex, BMI), the results of ultrasound, 
ALT, AST, High-Density Lipoprotein (HDL), Low-Density Lipoprotein 
(LDL), and TG, as well as weight before and after the intervention 
and any side-effects were recorded in a checklist.
Exclusion criteria were: taking ethanol and hepatotoxic drugs and 
suffering from cirrhosis of the liver, peptic ulcer, hyperthyroidism, 
severe anxiety, and severe liver, heart, and renal failure, and systemic 
diseases.
For both groups, modification of diet and intensification of physical 
activity were prescribed for three months. Meanwhile, intervention 
group was treated with green tea 500 mg tablet (Green teadin, 
Dineh Iran Company.), prepared from pulverised C. sinensis leaf and 
containing 50 mg total standardised polyphenol, three times per 
day. The participants were examined monthly for drug side-effects 
and were followed up for adherence to the drug use. At completion 
of the 3-month intervention, height, weight, liver enzymes and lipid 
profile were measured again; ultrasound was conducted again by 
the sonographer who conducted the baseline sonography, and the 
data were recorded.
STATISTICAL ANALYSIS
Data analysis was conducted by ANCOVA using SPSS version 19.0 
The p-value <0.05: were considered significant.
Groups
intervention diet and 
exercise+green tea
Control diet and 
exercise
Grade of fatty liver Number (%) Number (%)
Before 
intervention
Grade II 7 (27%) 4 (15.4%)
Grade I 19 (73%) 22 (84.6%)
After 
intervention
Grade II 0 (0%) 5 (19.2%)
Grade I 10 (38.5%) 21 (80.8%)
Grade 0 16 (61.5%) 0 (0%)
p-value <0.0001 0.59
[Table/Fig-1]: Comparison of fatty liver grade before and after intervention in green 
tea group and control group.
p<0.05: Significant
The levels of TG, HDL, LDL, ALT, AST, weight and BMI were recorded 
before and after intervention in both groups and mean changes in 
these variables were estimated. Except for the changes in LDL, the 
changes in other variables were significant in both groups (p<0.05) 
[Table/Fig-2].
DISCUSSION
In this study, the effect of C. sinensis tablets on NAFLD in 52 children 
aged 10-16 years with NAFLD was investigated. As NAFLD is seen 
in children over 10 years of age so, this age group was selected 
[4]. Intervention and control groups were not significantly different in 
terms of age, sex, weight, and BMI. Because fatty liver grade and lipid 
profile are associated with these variables, their confounding effects 
on results were neutralised and therefore the results are more likely 
to be attributed to the effect of C. sinensis in reducing lipidaemia, 
weight and BMI as well as improving fatty liver. Because antioxidant 
and anti-inflammatory properties of certain medicinal plants have 
already been confirmed and the effects of such plants in preventing 
steatohepatitis in the cases on high-fat diet are promising [20], The 
authors were encouraged to investigate the effect of C. sinensis 
consumption on NAFLD. In this study using C. sinensis tablet could 
improve fatty liver grade, while in control group, fatty liver did not 
Groups
difference after intervention (mean±Sd)
aSt u/l alt u/l ldl mg/dl hdl mg/dl triglyceride mg/dl Weight Kg Bmi (kg/m2)
Control 25.03±1.50 2.34±2.79 2.19±4.57 -1.64±1.35 10.07±8.97 1.53±0.42 0.06±0.18
Intervention -4.5±1.34 -13.07±3.18 -8.19±7.96 2.26±0.25 -40.76±25.36 -0.63±0.52 -1.18±0.26
p-value <0.0001 0.006 0.6 <0.01 0.034 0.006 0.006
[Table/Fig-2]: Comparison of mean difference in studied variables before and after intervention in green tea group and control group.
p<0.05: Significant
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improve. C. sinensis effect on the liver may be attributed to its 
antioxidant effect. C. sinensis did not cause significant decrease 
in LDL levels. Moreover, the changes in serum TG levels displayed 
significant effect of C. sinensis in decreasing TG levels compared to 
the effects of either diet or exercise. In addition to antioxidant effects, 
C. sinensis has also anti-hyperlipidemic effects that are possibly 
due to inhibitory effect of catechin in C. sinensis on phospholipase 
A2 that leads to decreased absorption of lipids [6]. C. sinensis has 
also been reported to have anti-apoptotic, nutrient-reducing, and 
inflammatory response-modulating effects [24]. Animal studies 
have shown that consumption of tea and catechin decreases 
triacylglycerol and serum total cholesterol concentration, prevents 
fat accumulation in the liver and body and stimulates thermogenesis 
[21]. In addition, drinking 690 mg catechin-containing beverage for 
12 weeks caused significant decrease in the body and subcutaneous 
fat in Japanese healthy men [25]. In the current study, the changes 
in serum HDL levels confirmed the significant effect of C. sinensis in 
increasing HDL levels compared to control group, representing its 
contribution to weight loss even in the short term. In a study using 
different doses, daily diet +1.3 mg/g EGCG led to weight loss in 
DSS-treated BALB/c mice [19]. However, indefinite results regarding 
the anti-obesity effects of C. sinensis have also been reported [15]. 
A study showed significant weight loss, decrease in BMI and waist 
circumference as well as similar decreases in the plasma levels of 
total cholesterol and LDL after 12 weeks’ treatment with high dose 
of EGCG in women aged 20-60 years. The anti-obesity mechanism 
might be, to a certain extent, related to inhibition of ghrelin secretion, 
which resulted in increased adiponectin [26].
In many studies, decrease in LDL has occurred after treatment with 
C. sinensis [27-30]. Decreased absorption of cholesterol and liver 
cholesterol concentration leads to increase in expression and activity 
of LDL receptors and this increased activity in the liver-specific cells 
cause cholesterol uptake from the blood flow [28]. In the present 
study, such decrease was also seen but it was not significant. This 
inconsistency in the findings can be due to differences in patients 
and duration of C. sinensis treatment and dose as well as the route 
of administration.
A study indicated that 24-week treatment with C. sinensis in 
overweight Japanese children, compared to those followed up 
on exercise and diet, caused significant decrease in LDL [27]. 
These children, however, were not NAFLD patients. In this regard, 
the study of Basu A et al., demonstrated significant decrease in 
weight and BMI, decrease in LDL and total cholesterol and increase 
in HDL after eight-week treatment with C. sinensis in obese men 
and women [30], which is consistent with the present findings 
regarding weight loss and HDL improvement. Consistent with the 
current study, Suliburska J et al., reported that supplementation 
with C. sinensis led to decreased total levels of cholesterol, LDL 
and triglyceride and increased levels of HDL and cholesterol in 
obese people [31]. Another study showed that taking C. sinensis 
caused significant decrease in LDL and remarkable increase in HDL 
[29]. In addition, eight-week treatment with C. sinensis extract did 
not cause any significant change in total cholesterol and TG, but 
resulted in increase in HDL concentration, decrease in adipose and 
improvement of lipolytic pathways [32]. In a study on diabetic people, 
one-month consumption of C. sinensis did not lead to significant 
change in total cholesterol, TGs, HDL, and LDL [33]. GrTPs can 
decrease the risk of certain complications such as cirrhosis, non-
alcoholic steatohepatitis, and hepatic cellular carcinoma [5].
In the present study, the levels of ALT and AST decreased after C. 
sinensis treatment as compared to control group. This medicinal 
plant has potential to prevent steatosis and therefore injuries due to 
oxidative stress, i.e., steatohepatitis. A study with mice reported that 
consumption of C. sinensis extract alongside exercise decreased 
plasma ALT level by 92% [34]. Significant decrease was observed 
in AST and ALP levels in rats orally administered with 10% aqueous 
C. sinensis extract compared to rats treated with 20% C. sinensis 
extract while the level of ALT in group fed with 20% of C. sinensis 
extract decreased significantly [35]. A study on diabetic people 
reported that only ALT increased significantly after C. sinensis 
consumption compared to controls. Other liver enzymes and the 
lipid factors did not change significantly [33]. Besides that, Hasanein 
AM et al., reported the most prominent decrease in the mean levels 
of AST, ALT and ALP was observed in the group on high-fat diet 
and treated daily with aqueous C. sinensis extract [36]. In the study 
of Pezeshki A et al., C. sinensis extract (500 mg tablet/day) caused 
significant decrease in ALT and AST compared to placebo in 20 to 
50 years-old patients with NAFLD [37], which is consistent with the 
present results on children aged 10-16 years. The present authors 
used C. sinensis tablet in the current study, but studies with animals 
have demonstrated that parenteral administration of C. sinensis is 
better than taking it orally [29].
The present study showed that C. sinensis compounds exerted 
protective effects against liver diseases in children and caused 
decrease in AST and ALT levels and hepatic fat accumulation, 
improvement of liver function and weight loss. The contribution 
of phenolic compounds and catechin in C. sinensis to these 
observations should be taken into account. However, such effects 
are more prominent when treatment is accompanied by exercise 
and appropriate diets. Although authors did not observe any side-
effects, lack of prescribing polyphenolic compounds in high doses 
for children should be seriously considered because long-term use 
of C. sinensis extract in the mice on high-cholesterol diet has led to 
adverse effects and induced liver injury [9]. Overall, inconsistency 
in results can be due to differences in duration of C. sinensis 
treatment, dose, the type and compounds of the tablet or extract 
used, people’s habitual drinking of C. sinensis in some regions and 
the form of administration (tablet, syrup, bag, brewed, etc.,).
LIMITATION
Limitations of the current study was small sample size and short 
follow-up duration. It is recommended to design future study on 
larger sample and longer follow-up.
CONCLUSION
With regard to the positive effects of C. sinensis in decreasing weight, 
BMI and hepatic fat accumulation as well as improving liver function, 
decreasing liver enzymes ALT and AST and improving blood lipid 
profile in children aged 10-16 years in this study, prescription of 
this medicinal plant, in 500 mg dose, is recommended particularly 
for preventing development of liver diseases in children especially 
NAFLD. These effects can be due to certain compounds such as 
polyphenols especially catechin in C. sinensis and its antioxidant 
and anti-hyperlipidemic effects.
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